Alendronate

Overview

Alendronate (Fosamax®) is an oral bisphosphonate that inhibits bone resorption by suppressing osteoclastic activity. In veterinary medicine, its use is considered extra-label and investigational, with limited clinical experience in dogs and cats.

The drug has been explored primarily for conditions associated with increased bone resorption or calcium imbalance, including idiopathic hypercalcemia in cats, feline tooth resorption, bone pain, and as an adjunctive therapy in canine osteosarcoma.

Oral bioavailability of alendronate is extremely low (<2% in most species; Papich reports 3-7%) and is dramatically reduced by food or non-water beverages. In humans, taking alendronate with coffee or orange juice reduced bioavailability by 60% versus plain water. Accurate dosing requires strict water-only administration on an empty stomach with no food for at least 30 minutes after dosing.

Clinical considerations: Alendronate has a very long terminal half-life once incorporated into bone — It is estimated that the terminal elimination
half-life is ≈1000 days in dogs and ≈10 years in humans; however,
once incorporated into bone, alendronate is no longer active. — the long bone half-life reflects skeletal retention rather than ongoing activity. Potential risks include gastrointestinal irritation, esophageal erosions, and hypocalcemia. Because safety data in animals are limited, use should be reserved for cases where potential benefits clearly outweigh the risks.

Indications

Alendronate is used on an extra-label basis in small animal practice for conditions associated with excessive bone resorption or calcium imbalance. Its use remains limited, and it should be reserved for selected cases where other therapies are inadequate or contraindicated.

• Idiopathic hypercalcemia in cats: Used to reduce serum ionized calcium concentrations in cats with refractory or persistent idiopathic hypercalcemia .
• Feline tooth resorption: Administered to slow or arrest the progression of feline odontoclastic resorptive lesions by inhibiting osteoclastic activity at tooth and alveolar bone surfaces.
• Bone pain in dogs: Used as an adjunctive therapy to reduce pain associated with bone tumors, including primary bone neoplasia.
• Osteosarcoma (adjunctive use in dogs): May be incorporated as part of a multimodal treatment plan to inhibit tumor-associated bone resorption and potentially improve comfort.
• Osteogenesis imperfecta (extra-label, dogs and cats): Osteogenesis imperfecta (extra-label, dogs and cats): Bisphosphonate supplementation has been used to support bone density in osteogenesis imperfecta. : dogs 0.5-1 mg/kg PO q24h on empty stomach; cats 10 mg/cat PO once weekly on empty stomach. Effectiveness of bisphosphonates for OI in dogs and cats has not been formally evaluated and remains investigational.

Due to limited clinical data, uncertain long-term safety, and challenges with dosing and administration, alendronate use in dogs and cats should be considered investigational and undertaken with caution.

Dosage (Reference)

Dog

In dogs, alendronate is used on an extra-label basis. Clinical experience is limited, and dosing recommendations are based on small studies and case reports. Accurate administration on an empty stomach is critical to ensure absorption and reduce esophageal irritation.

Cat

In cats, alendronate is most commonly used for idiopathic hypercalcemia and feline tooth resorption. Doses are prescribed as total milligrams per cat (NOT mg/kg), and careful administration techniques are required to reduce esophageal exposure.

Warnings & Precautions

Alendronate use in veterinary patients should be approached with caution due to limited clinical experience, uncertainty regarding optimal dosing, and potential for serious gastrointestinal adverse effects. At present, its use in small animals should be considered investigational.

• Hypersensitivity: Contraindicated in patients with known hypersensitivity to alendronate or other bisphosphonates.
• Esophageal irritation and injury: Bisphosphonates may cause esophagitis, esophageal erosions, or ulcers. Although the true risk in dogs and cats is unknown, strict adherence to administration guidelines is critical to minimize esophageal exposure.
• Esophageal motility disorders: Use cautiously in patients with conditions that delay esophageal emptying, as prolonged contact may increase the risk of mucosal injury.
• Renal disease: Use with caution in patients with renal impairment. In humans, alendronate is not recommended in severe renal dysfunction, and similar caution is advised in veterinary patients.
• Hypocalcemia: Serum calcium abnormalities should be corrected prior to initiating therapy. Alendronate may exacerbate hypocalcemia.
• Calcium and vitamin D status: Ensure adequate dietary intake or supplementation of calcium and vitamin D, as deficiencies may increase the risk of adverse skeletal effects.
• Osteonecrosis of the jaw: Bisphosphonate-associated osteonecrosis of the jaw has been reported in humans and has been documented in at least one cat. Risk factors include invasive dental procedures, poor oral hygiene, cancer, corticosteroid therapy, anemia, infection, and coagulopathies.
• Dental procedures: Use caution in patients requiring dental extractions or invasive oral procedures during therapy due to potential risk of delayed healing or jaw complications.
• Investigational use: Limited research data, potential for gastrointestinal injury, medication cost, and uncertainty regarding long-term safety may limit clinical usefulness in small animals.
• Pregnancy & lactation: Rat studies: 2 mg/kg decreased post-implantation survival; 1 mg/kg decreased pup weight gain; 10 mg/kg incomplete fetal ossification; maternal hypocalcemia → protracted parturition. No fetal effects in rabbits during organogenesis. Milk excretion unknown but unlikely to be absorbed in offspring due to low oral bioavailability. Use only when maternal benefits outweigh risks.
• Laboratory interference: Alendronate may interfere with technetium-99m-diphosphonate bone scans (both drugs bind hydroxyapatite). Inform imaging team during/after therapy.

Drug Interactions

The following drug interactions with alendronate have been reported or are theoretical in humans or animals and may be of clinical significance in veterinary patients. Unless otherwise noted, concurrent use is not necessarily contraindicated, but potential risks should be weighed and appropriate monitoring performed.

• Aminoglycosides (e.g., amikacin, gentamicin): Concurrent use may increase the risk of hypocalcemia and nephrotoxicity. Use cautiously and monitor serum calcium and renal function.
• Aspirin: BSAVA 11e explicitly prohibits the combination due to increased risk of upper GI adverse events. Plumb’s notes theoretical risk of GI toxicity and renal impairment. Do not combine alendronate with aspirin.
• Calcium-, Aluminum-, or Magnesium-containing oral products: These agents can significantly decrease oral bioavailability of alendronate. Patients should receive nothing by mouth other than water for at least 2 hours before and after alendronate administration.
• Loop diuretics (e.g., furosemide): Concurrent use may increase the risk of hypocalcemia. Monitor serum calcium and renal function.
• Estrogens (e.g., estradiol, diethylstilbestrol): May have additive effects on bone density when used concurrently.
• H₂-receptor antagonists (e.g., famotidine, ranitidine): Concurrent use may increase systemic levels of both drugs.
• NSAIDs (e.g., carprofen, meloxicam, robenacoxib): Theoretically increased risk of gastrointestinal toxicity and renal impairment. Use together cautiously and monitor for GI signs and renal dysfunction.
• Proton pump inhibitors (e.g., omeprazole, pantoprazole): Concurrent use may decrease the therapeutic effects of alendronate; avoid combination when possible.

Side Effects & Overdose

Side Effects

There is limited information regarding the specific adverse effect profile of alendronate in dogs and cats. Most available data are extrapolated from human use and limited veterinary reports.

• Upper gastrointestinal irritation: Bisphosphonates may cause esophagitis, esophageal erosions, or ulcers. This risk is well-documented in humans, but the true risk in dogs and cats remains unclear.
• Gastrointestinal upset: Vomiting, inappetence, and nonspecific GI discomfort have been anecdotally reported in dogs receiving alendronate.
• Esophageal injury (theoretical): Prolonged esophageal contact time may increase the risk of irritation or ulceration. Post-dosing activity (eg, walking or playing for 30 minutes in dogs) or measures to increase salivation in cats have been suggested to reduce risk.
• Musculoskeletal pain: Bone, joint, or muscle pain has been reported in humans and is a potential concern in veterinary patients.
• Atypical fractures: Atypical fractures have been associated with long-term bisphosphonate use in humans. pathological fractures have been reported in cats after prolonged use (5-9 years) .

Overdose

Key Notes

Practical clinical considerations that may help guide appropriate use of alendronate in dogs and cats, particularly given the limited veterinary experience with this drug:

• Investigational use: Alendronate use in small animals remains limited and should be considered investigational, with treatment decisions based on individual risk-benefit assessment.
• Species-specific dosing: In cats, dosing is commonly based on a fixed total dose (mg/cat) rather than body weight, whereas in dogs both mg/dog and mg/kg regimens have been reported.
• Delayed pharmacologic clearance: The drug binds strongly to bone and persists for long periods, meaning effects may continue even after discontinuation.
• Slow clinical response: Therapeutic effects, particularly for hypercalcemia or bone pain, may take days to weeks to become evident.
• Not a first-line therapy: Alendronate is generally reserved for refractory or specific conditions when more established treatments are ineffective or contraindicated.
• Dental considerations: Careful oral and dental assessment is advisable prior to long-term therapy, especially in patients with existing dental disease.
• Client education is essential: Owners should be informed that this medication has limited veterinary data and requires close monitoring and strict administration protocols.